Cardiff Lexingto Stock Price, News & Analysis

Cardiff Lexington Corporation (OTCQB: CDIX) is described in its public disclosures and news releases as a targeted healthcare holding company focused on acquiring and building middle-market niche health care clinics, primarily in Orthopedics, Spine Care, and Pain Management. Although its legacy industry classification references "Software and Other Prerecorded Compact Disc, Tape, and Record Reproducing" within the Manufacturing sector, the company’s more recent communications consistently present Cardiff Lexington as a healthcare-focused organization.

According to multiple company press releases, Cardiff Lexington’s strategy centers on locating, acquiring, and developing middle-market healthcare businesses. The company emphasizes a partnership-driven culture and a service-based approach that highlights core values such as service excellence, teamwork, accountability, and performance. This focus is intended to guide how acquired clinics are integrated and operated within the broader holding company structure.

Business model and operating focus

Cardiff Lexington identifies itself as a holding company that builds value by owning and managing healthcare clinics. Public statements explain that a substantial majority, and in some instances all, of the company’s revenue is derived from its operating subsidiary Nova Ortho and Spine, LLCFlorida and Georgia. These centers focus on treating traumatic injury patients and providing a range of services that include diagnostic and surgical procedures, primary care evaluations, interventional pain management, and specialty consultations.

This structure means that Cardiff Lexington’s financial performance and operating metrics are closely tied to the patient volume, service mix, and operational efficiency of Nova Ortho and Spine. Company disclosures also reference the use of non-GAAP financial measures alongside GAAP results to provide additional perspective on its financial condition and operating performance.

Geographic footprint and patient focus

Based on recent press releases, Nova Ortho and Spine operates multiple locations across Florida and Georgia, described as regional primary specialty and ancillary care facilities. The company highlights its work with traumatic injury victims and its provision of orthopedic, spine care, and pain management services. In at least one instance, Cardiff Lexington has noted that Nova Ortho and Spine is expanding into underserved and rural areas of Florida, including performing procedures at Doctor's Memorial Hospital in Perry, Florida, in Taylor County. Public communications characterize Taylor County as a region with limited healthcare provider availability and significant patient needs, and Cardiff Lexington has framed this expansion as part of its commitment to serving underserved populations.

Corporate structure and capital markets activity

Cardiff Lexington is incorporated in Nevada and has identified Las Vegas, Nevada, as the location of its principal executive offices in SEC filings. The company’s common stock is quoted on the OTCQB Venture Market under the symbol CDIX. In a January 2026 news release, Cardiff Lexington announced a 1-for-3 reverse stock split of its issued and outstanding common stock. The reverse split was implemented with the stated primary purpose of supporting compliance with the minimum bid price requirement for a planned listing on the Nasdaq Capital Market. Following the reverse split, the company indicated that its ticker would temporarily trade as CDIXD for 20 trading days, while continuing to be quoted on the OTCQB.

In December 2025, Cardiff Lexington filed a Form S-1 registration statement with the U.S. Securities and Exchange Commission. The preliminary prospectus notes that the company’s common stock is quoted on the OTCQB and that it has applied for listing on The Nasdaq Capital Market under the symbol "CDIX" in connection with a public offering. The S-1 filing also confirms that Cardiff Lexington is a smaller reporting company under SEC rules and details the proposed public offering of common stock, subject to the registration statement becoming effective and the Nasdaq listing application being approved.

Governance and leadership changes

Cardiff Lexington has reported governance developments through both press releases and SEC filings. In a December 2025 news release, the company announced that Daniel Thompson would retire as Chairman of the Board of Directors, effective December 31, 2025, after a long tenure. The same communication stated that Alex Cunningham, the company’s President and Chief Executive Officer, would assume the additional role of Chairman. A Form 8-K filed in January 2026 further documented Mr. Thompson’s resignation from the Board of Directors and confirmed that his departure was not due to any disagreement with the company on matters related to operations, policies, or practices. The 8-K also recorded the appointment of Alex Cunningham as the new Chairman of the Board.

Financial reporting and advisory relationships

Cardiff Lexington regularly releases quarterly financial results via newswire, including detailed summaries of revenue, gross profit, operating income or loss, interest expense, net loss, and non-GAAP adjusted EBITDA. These releases often discuss changes in revenue and margins compared with prior periods, as well as the impact of one-time non-cash adjustments related to billing realization rates and line-of-credit accounting.

In November 2025, the company announced an advisory agreement with Greentree Financial Group, Inc., a consulting firm that focuses on corporate governance, financial reporting, and public markets compliance. Cardiff Lexington stated that Greentree would assist with audit processes, S-1 filing support, SEC and exchange comment responses, governance initiatives, and coordination with professional advisors. The company has linked this engagement to its broader effort to advance an uplisting strategy and strengthen financial reporting and compliance practices.

Growth, expansion, and strategic focus

Across multiple press releases, Cardiff Lexington has described its approach as focused on both organic growth within Nova Ortho and Spine and potential mergers and acquisitions of additional middle-market healthcare clinics. The company has cited increasing patient volumes at Nova Ortho and Spine locations and has referenced plans to expand the footprint of these facilities in Florida and Georgia. Statements from management have also connected the company’s growth strategy to its efforts to access a major U.S. exchange, with uplisting described as an important step in enhancing visibility among investors.

Company communications emphasize that Nova Ortho and Spine provides a range of services to traumatic injury patients, including diagnostic imaging and testing, surgical procedures, primary care evaluations, interventional pain management, and specialty consultations. These services are delivered through a network of regional centers and, in some cases, through partnerships with hospitals such as Doctor's Memorial Hospital in Perry, Florida. Cardiff Lexington positions this network as central to its identity as a healthcare holding company.

Regulatory reporting and non-GAAP measures

Cardiff Lexington prepares its consolidated financial statements in accordance with U.S. generally accepted accounting principles (GAAP). In its earnings releases, the company also presents non-GAAP financial measures, such as adjusted revenue and adjusted EBITDA, which exclude certain non-cash charges or one-time adjustments. The company states that these non-GAAP measures are intended to provide additional insight into its financial condition and results, while noting that such measures should be considered in conjunction with, and not as a substitute for, GAAP measures.

Through its SEC filings, including periodic reports and the S-1 registration statement, Cardiff Lexington provides detailed financial statements, notes, and disclosures regarding its assets, liabilities, mezzanine equity, preferred stock series, common stock, additional paid-in capital, and accumulated deficit. The S-1 also outlines risk factors, offering details, and information about the company’s status as a smaller reporting company.

Stock information and trading venue

Cardiff Lexington’s common stock is quoted on the OTCQB Venture Market under the symbol CDIX. In connection with the January 2026 reverse stock split, the company announced that the stock would trade on a split-adjusted basis and that the ticker would temporarily appear as CDIXD for a limited period. The company has also disclosed that it has applied to list its common stock on The Nasdaq Capital Market under the same symbol, with the closing of a proposed public offering contingent on the success of this uplisting application.

Summary

In summary, Cardiff Lexington Corporation is presented in its own disclosures as a Nevada-incorporated, healthcare-focused holding company whose operations are concentrated in orthopedic, spine care, and pain management services delivered through its Nova Ortho and Spine subsidiary in Florida and Georgia. Its recent activities include financial reporting, corporate governance changes, an advisory engagement to support public market compliance and uplisting efforts, a reverse stock split aimed at meeting exchange listing requirements, and the filing of a Form S-1 registration statement for a proposed public offering and Nasdaq listing.